Nephros Inc. (NASDAQ:NEPH) Short Interest Up 28.8% in March

Nephros Inc. (NASDAQ:NEPH) was the target of a large increase in short interest in March. As of March 13th, there was short interest totaling 5,414 shares, an increase of 28.8% from the February 26th total of 4,205 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 35,028 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NEPH. Kestra Advisory Services LLC purchased a new stake in shares of Nephros during the 4th quarter worth about $29,000. Dimensional Fund Advisors LP bought a new stake in shares of Nephros in the 3rd quarter valued at approximately $64,000. Heron Bay Capital Management acquired a new position in Nephros in the fourth quarter worth approximately $66,000. Citadel Advisors LLC increased its holdings in Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after buying an additional 4,655 shares during the last quarter. Finally, XTX Topco Ltd raised its position in Nephros by 48.5% during the fourth quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after acquiring an additional 7,062 shares in the last quarter. 41.10% of the stock is owned by institutional investors and hedge funds.

Nephros Stock Up 5.3%

NEPH stock opened at $2.98 on Wednesday. The company has a 50 day moving average of $3.81 and a two-hundred day moving average of $4.55. The company has a market cap of $31.71 million, a price-to-earnings ratio of 27.09 and a beta of 1.42. Nephros has a 12-month low of $1.64 and a 12-month high of $6.42.

Nephros (NASDAQ:NEPH) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. Nephros had a net margin of 6.35% and a return on equity of 12.22%. The business had revenue of $4.73 million for the quarter, compared to analysts’ expectations of $4.45 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.